This inventor holds 1 USPTO granted patent. Top assignee: University of Kansas. Active years: 2024.
Company Filing History:
Years Active: 2024
Title: Innovations of Patrick Andrew Ross
Introduction
Patrick Andrew Ross is an accomplished inventor based in Lawrence, Kansas. He has made significant contributions to the field of pharmaceuticals, particularly through his innovative work on Kifunensine derivatives. His research focuses on compounds that have the potential to enhance the efficacy of anti-CD20 monoclonal antibodies.
Latest Patents
Patrick holds a patent for Kifunensine derivatives, which relates to compounds according to Formula I or a pharmaceutically acceptable salt and/or solvate thereof. The patent highlights the significant upregulation of CD20 by the inhibition of α-mannosidase enzymes. This innovation is crucial as it potentiates the activity of anti-CD20 monoclonal antibodies and sensitizes cell lines that are resistant to these antibodies. He has 1 patent to his name.
Career Highlights
Patrick Andrew Ross is affiliated with the University of Kansas, where he conducts his research and development. His work has garnered attention for its potential applications in treating diseases that involve CD20, such as certain types of cancer.
Collaborations
Among his notable coworkers are Mark Patrick Farrell and Suresh Eknath Kurhade. Their collaborative efforts contribute to the advancement of research in the field of pharmaceuticals.
Conclusion
Patrick Andrew Ross exemplifies the spirit of innovation in the pharmaceutical industry. His work on Kifunensine derivatives showcases the potential for new treatments that can improve patient outcomes.